Celine practices general corporate and securities law, with an emphasis on the representation of emerging companies, venture capital funds and public companies. Celine represents her clients throughout the business life cycle in matters such as venture financings, mergers & acquisitions, public offerings, and Securities and Exchange Commission reporting and compliance.
AIM Intelligent Machines Announces $50 Million Funding
June 10, 2025
Cooley advised AIM Intelligent Machines, the world’s first embodied artificial intelligence platform for earthmoving machinery, on its $50 million fundraise from various investors, including Khosla Ventures and General Catalyst. AIM will use the funding to transform the global construction and mining industries. Partner Sale Kwon led the Cooley team advising AIM.
Cooley Represents Wheeler Bio in $35M Series A-1 Financing Round
March 20, 2025
Cooley represented Wheeler Bio in the closing of its $35 million Series A-1 financing round. This funding will support Wheeler Bio’s ongoing efforts to expand its capabilities and accelerate the advancement of its partners’ therapies. Lawyers Sale Kwon and Emily Lee led the Cooley team advising Wheeler Bio, a developer of biomanufacturing services designed to translate therapeutic innovations into clinical impact.
Cooley advised Baseten, the top inference platform for artificial intelligence (AI)-native products, on its $75 million Series C financing, bringing its total funding to $135 million.
Cooley advised Delphix, a vendor of test data management software, on its acquisition by Perforce, a provider of solutions to enterprise teams requiring productivity, visibility and scale along the development life cycle.
Blue Owl Capital Invests up to $1.05 Billion in BridgeBio Pharma
January 17, 2024
Cooley advised Blue Owl Capital, a top asset manager redefining alternatives, on its strategic investment a $300 million royalty financing and a $450 million credit facility in BridgeBio Pharma, a commercial-stage biopharmaceutical company focused on genetic diseases and cancers.
